Text Size
Trial record 16 of 21 for:    Metachromatic Leukodystrophy
Previous Study | Return to List | Next Study

Human Placental-Derived Stem Cell Transplantation (HPDSC)

This study is currently recruiting participants.
Verified March 2013 by New York Medical College
Sponsor:
Information provided by (Responsible Party):
New York Medical College
ClinicalTrials.gov Identifier:
NCT01586455
First received: April 25, 2012
Last updated: April 18, 2013
Last verified: March 2013
History of Changes
  Purpose

The purpose of this clinical trial is to investigate the safety of human placental-derived stem cells (HPDSC) given in conjunction with umbilical cord blood (UCB) stem cells in patients with various malignant or nonmalignant disorders who require a stem cell transplant. Patients will get either full dose (high-intensity) or lower dose (low intensity) chemo- and immunotherapy followed by a stem cell transplantation with UCB and HPDSC.


Condition Intervention Phase
Mucopolysaccharidosis I
Mucopolysaccharidosis VI
Adrenoleukodystrophy
Niemann-Pick Disease
Metachromatic Leukodystrophy
Wolman Disease
Krabbe's Disease
Gaucher's Disease
Fucosidosis
Batten Disease
Severe Aplastic Anemia
Diamond-Blackfan Anemia
Amegakaryocytic Thrombocytopenia
Myelodysplastic Syndrome
Acute Myelogenous Leukemia
Acute Lymphocytic Leukemia
 Drug: Human Placental Derived Stem Cell
 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders

Resource links provided by NLM:

Genetics Home Reference related topics: adenosine deaminase deficiency Chanarin-Dorfman syndrome CHMP2B-related frontotemporal dementia cholesteryl ester storage disease Diamond-Blackfan anemia familial acute myeloid leukemia with mutated CEBPA Farber lipogranulomatosis frontotemporal dementia with parkinsonism-17 fucosidosis Gaucher disease GRN-related frontotemporal dementia inclusion body myopathy with early-onset Paget disease and frontotemporal dementia juvenile Batten disease Krabbe disease Kufs disease leukoencephalopathy with vanishing white matter MECP2 duplication syndrome megalencephalic leukoencephalopathy with subcortical cysts metachromatic leukodystrophy mucopolysaccharidosis type I mucopolysaccharidosis type VI Niemann-Pick disease PPM-X syndrome purine nucleoside phosphorylase deficiency Renpenning syndrome Schindler disease succinic semialdehyde dehydrogenase deficiency Wolman disease X-linked adrenoleukodystrophy X-linked severe combined immunodeficiency ZAP70-related severe combined immunodeficiency Zellweger spectrum
U.S. FDA Resources

Further study details as provided by New York Medical College:

Primary Outcome Measures:
  • Safety [ Time Frame: 100 days ] [ Designated as safety issue: Yes ]
    to evaluate the safety of human placental-derived stem cells (HPDSC) administered in conjunction with umbilical cord blood (UCB) stem cells in patients with malignant and non-malignant diseases.


Secondary Outcome Measures:
  • donor chimerism [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    donor chimerism will be assessed at set timepoints

  • engraftment [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Survival [ Time Frame: 100 days and 180 days ] [ Designated as safety issue: No ]
  • Relapse [ Time Frame: 100 days and 180 days ] [ Designated as safety issue: No ]
  • Mortality [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Estimated Enrollment: 30
Study Start Date: March 2013
Estimated Study Completion Date: December 2019
Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group A
related cord blood with ≥3/6 HLA match to the patient and related HPDSC
 Drug: Human Placental Derived Stem Cell
Infusions of thawed HPDSC to be given following UCB infusion.
Other Name: HPDSC
Experimental: Group B
unrelated cord blood with ≥ 4/6 HLA match to the patient and unrelated HPDSC
 Drug: Human Placental Derived Stem Cell
Infusions of thawed HPDSC to be given following UCB infusion.
Other Name: HPDSC
Experimental: Group C
unrelated cord blood with ≥4/6 HLA match to the patient but related to HPDSC
 Drug: Human Placental Derived Stem Cell
Infusions of thawed HPDSC to be given following UCB infusion.
Other Name: HPDSC
Experimental: Group D
double unrelated cord blood units with ≥4/6 HLA match to patient and each other and unrelated HPDSC
 Drug: Human Placental Derived Stem Cell
Infusions of thawed HPDSC to be given following UCB infusion.
Other Name: HPDSC

  Eligibility

Ages Eligible for Study:   up to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • < 55 years of age
  • Life expectancy greater than 3 months
  • Lansky performance status ≥ 50% (children) or Karnofsky performance status ≥ 70% (adults) or ECOG performance status 0-2 (adults)
  • DLCO > 50 percent predicted
  • Left ventricular ejection fraction > 40% estimated
  • Creatinine clearance or estimated GFR . 60 mL/min/1.73m2
  • Serum bilirubin < 1.5x upper limit of normal
  • Transaminases < 3x upper limit of normal
  • Absence of uncontrolled infection
  • HIV negative

Exclusion Criteria:

  • Fanconi Anemia
  • Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
  • Uncontrolled infection
  • Pregnant or breast-feeding females
  • Received other investigational agents within 30 days prior to the start of the conditioning regimen
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01586455

Contacts
Contact: Mitchell S Cairo, MD 914-594-3650 mitchell_cairo@nymc.edu
Contact: Lauren Harrison, MSN 978-993-4372 lauren_harrison@nymc.edu

Locations
United States, New York
New York Medical College Recruiting
Valhalla, New York, United States, 10595
Contact: Mitchell Cairo, MD     914-594-3650     mitchell_cairo@nymc.edu    
Contact: Lauren Harrison, MSN     6172857844     lauren_harrison@nymc.edu    
Sponsors and Collaborators
New York Medical College
Investigators
Principal Investigator: Mitchell S Cairo, MD New York Medical College
  More Information

No publications provided

Responsible Party: New York Medical College
ClinicalTrials.gov Identifier: NCT01586455     History of Changes
Other Study ID Numbers: NYMC 550, NYMC IRB L-10,733
Study First Received: April 25, 2012
Last Updated: April 18, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by New York Medical College:
umbilical cord blood
stem cell transplantation
placental stem cell
inborn errors of metabolism
marrow failure
 Severe Combined Immunodeficiency Disease
AML
ALL
MDS

Additional relevant MeSH terms:
Leukodystrophy, Globoid Cell
Leukodystrophy, Metachromatic
Anemia
Anemia, Aplastic
Fucosidosis
Gaucher Disease
Leukemia
Leukemia, Lymphoid
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Myeloid, Acute
Leukemia, Myeloid
Mucopolysaccharidosis I
Mucopolysaccharidoses
Mucopolysaccharidosis VI
Myelodysplastic Syndromes
 Preleukemia
Niemann-Pick Diseases
Niemann-Pick Disease, Type A
Niemann-Pick Disease, Type C
Thrombocytopenia
Wolman Disease
Cholesterol Ester Storage Disease
Adrenoleukodystrophy
Aphasia, Primary Progressive
Pick Disease of the Brain
Frontotemporal Dementia
Anemia, Diamond-Blackfan
Neuronal Ceroid-Lipofuscinoses
Hematologic Diseases
Bone Marrow Diseases

ClinicalTrials.gov processed this record on May 16, 2013